Archimedic Blog

Most founders treat reimbursement like taxes: something to deal with once the real work is done. Build the device, get it cleared, then figure out how to get paid. That sequence is backwards, and it's...

If you are an early-stage medtech founder who thinks a $335 million exit has nothing to teach you, this one is worth five minutes of your time.

In 2026, Artivion, Inc. paid $135 million upfront, with u...

Olympus Corporation just agreed to pay $270 million for a balloon filled with saline… Take a moment with that.

At $14.5 million in sales, that’s more than an 18x on a times-revenue basis. For what is, ...

What is the number one thing investors look for in a start-up?

"Disruptive technology" and "market opportunity" are table stakes just to get in the room.

What consistently closes deals is the leadership...

Raising funds for a MedTech startup isn’t just about pitching investors—it’s about building relationships, gathering insights, and positioning your innovation for long-term success. In a recent Linked...

It’s been just over a year since I joined Robin Hood Ventures as an angel investor. While many investors in the group are far more seasoned, I’ve gained invaluable insights by diving into the due dili...

You’ve probably heard of Proteus.  mAt one time it was the darling of digital health. But within a single year, Proteus went from a $1.5B valuation to a fire sale at $15m. Here's a recreation of event...

Happy Wednesday to 602 motivated medtech business leaders. Here's one short tip on how to refine your medtech strategy.

In this week's issue, I'm going to break down the #1 thing that prevents medt...